Mantle Cell Lymphoma | Tumor

CURE’s mantle cell lymphoma (MCL) page features the latest cancer news and updates on mantle cell lymphoma Through articles, videos, podcasts, and more, CURE brings readers the insights of experts, cancer survivors, patients, and advocates to ensure everyone is up to date in mantle cell lymphoma.

Emerging Treatments for Mantle Cell Lymphoma

September 10th 2019

BTK inhibitors and CAR-T cell therapies for mantle cell lymphoma help to expand the treatment landscape for patients.

Novel Agents May Lead to a Chemo-Free Future for Patients With Mantle Cell Lymphoma

September 6th 2019

One expert discusses the current treatment options for patients with mantle cell lymphoma as well as the potential shift away from chemotherapy in the future.

Study Unveils Family Risk for Certain Types of Blood Cancer

August 14th 2019

Those with a first-degree relative diagnosed with certain blood cancers may be at an increased risk for developing the disease themselves.

Study Highlights Need for Frailty Testing Among Older Adults with Blood Cancer

August 5th 2019

A slower walking pace among older adults with blood cancer can be a sign of frailty – which could be useful to know when tailoring one’s care to increase survival and lower hospitalizations.

Cell Therapies May Help Overcome Drug Resistance in Patients With Mantle Cell Lymphoma

July 1st 2019

Breakthroughs such as CAR-T cell therapy in the treatment of mantle cell lymphoma could help patients overcome drug resistance and ultimately live longer, according to Dr. Michael Wang.

Patients With Mantle Cell Lymphoma Experience Response to Imbruvica Combinations

June 27th 2019

Newer treatments for MCL offer hope to patients living with the fast-growing and challenging-to-treat disease.

Targeted Therapies for Advanced MCL May Improve Outcomes as Front-line Treatment

June 26th 2019

Mantle cell lymphoma remains incurable, despite researchers’ best efforts. However, new treatment options show promise in the relapsed/refractory setting and may improve patient outcomes if moved to the front-line, according to Dr. Reem Karmali.

Emergence of Treatment Options in Mantle Cell Lymphoma Excites Many

June 13th 2019

An expert discusses the exciting approaches under investigation in mantle cell lymphoma and insight into where future research should focus.

Imbruvica Shows Promise as Maintenance Therapy for Patients With MCL

June 13th 2019

Maintenance therapy with Imbruvica appeared to be a feasible option for patients with mantle cell lymphoma, according to Dr. Reem Karmali.

CAR-T Cell Therapy Shows Potential in Relapsed/Refractory Mantle Cell Lymphoma

June 12th 2019

Treatment with lisocabtagene maraleucel, also known as liso-cel, demonstrated clinical activity and appeared tolerable among patients with relapsed/refractory mantle cell lymphoma.

Researcher Highlights the Need for Curative Approach to Mantle Cell Lymphoma Treatment

May 20th 2019

While many advances have been made in the treatment landscape of MCL, the need for curative treatment options may be where future research goes.

Newer Drug Combinations Offer Hope to Those With Mantle Cell Lymphoma

May 17th 2019

One expert discusses the significance of newer drugs and the role they play in helping patients with relapsed or refractory disease.

Investigational Drug May Help Drug Resistance in Mantle Cell Lymphoma Treatment

May 17th 2019

A small molecule drug may help to overcome resistance to Imbruvica in patients with MCL, according to preclinical study findings from The University of Texas MD Anderson Cancer Center.

Despite Advances, Many Questions Remain in Mantle Cell Lymphoma Treatment

April 9th 2019

Izidore S. Lossos, M.D., discussed how questions remain on how to find the least toxic therapies that will prolong survival in both young and elderly patients with mantle cell lymphoma.

Study Examines Combination Regimen for Treating CINV During and After Chemo

April 8th 2019

A recent clinical trial is examining the combination regimen of netupitant plus palonosetron (NEPA), with hopes that it can curb nausea and vomiting both before and after chemotherapy in patients with peripheral T-cell lymphoma, Hodgkin lymphoma, mantle cell lymphoma and diffuse large B-cell lymphoma.

Paging Dr. Web

March 21st 2019

Surprise! You can’t believe everything you read on the internet!

Therapies and Challenges in the Evolving Treatment of Mantle Cell Lymphoma

March 15th 2019

While it is an exciting time for the treatment of mantle cell lymphoma (MCL), challenges still remain, according to Andre Goy, M.D., MS.

Panel Finds Value in Certain Maintenance Therapies for Patients with Lymphoma

March 14th 2019

With the evolving landscape of maintenance therapies to treat patients with lymphoma following auto-HCT, a panel consensus recommended four grade A options for physicians to utilize.

Oral Blood Thinner May Reduce Blood Clots in High-Risk Patients with Cancer

March 8th 2019

The oral blood thinner Xarelto (rivaroxaban) significantly reduced blood clots for high-risk patients with cancer being treated in the outpatient setting, according to results from the CASSINI trial.

Combination Use of Treanda Plus Calquence Shows Promise in Mantle Cell Lymphoma Subset

February 17th 2019

The combination regimen demonstrated improved efficacy outcomes with a tolerable profile among patients with relapsed/refractory mantle cell lymphoma.

Treatment Landscape Continues to Evolve in Mantle Cell Lymphoma

February 16th 2019

In patients with mantle cell lymphoma, the introduction of BTK inhibitors continues to shape the treatment landscape.

Examining Overtreatment in Mantle Cell Lymphoma

January 29th 2019

While some high-risk patients with mantle cell lymphoma may benefit from aggressive initial therapy, a recent study found that this may not be necessary for others who could benefit from more targeted therapies.

Zanubrutinib Granted Breakthrough Designation for Mantle Cell Lymphoma

January 15th 2019

The Food and Drug Administration (FDA) has granted the investigational BTK inhibitor zanubrutinib (BGB-3111) a breakthrough therapy designation for the treatment of adult patients with mantle cell lymphoma (MCL) who have previously received at least one prior therapy, according to BeiGene, the company manufacturing the agent.

Investigational BTK Inhibitor Sparks Responses in Patients with Mantle Cell Lymphoma

December 26th 2018

The investigational targeted drug zanubrutinib (BGB-3111) appeared to be highly active, inducing an overall response rate of 83.5 percent in patients with relapsed/refractory mantle cell lymphoma, who were treated in a single-arm, open-label, multicenter, phase 2 trial.

Circulating Tumor DNA Serves as Early Predictor in Mantle Cell Lymphoma Outcomes

December 11th 2018

Measuring circulating tumor DNA in the blood of patients with advanced mantle cell lymphoma may be a viable way to predict how well they will respond to specific therapies.

Feasibility of Post-Transplant Velcade in Mantle Cell Lymphoma Encourages Further Study

December 10th 2018

Treatment with Velcade (bortezomib) following induction chemotherapy and stem cell transplantation seemed safe and effective for untreated patients with mantle cell lymphoma, encouraging further evaluation for more active, less toxic targeted agents.

Two Are Better Than One: Alternating Chemoimmunotherapy Regimens May Benefit Those with MCL

December 7th 2018

A recent study looked at a new combination to determine what would happen if untreated patients eligible for transplant were given alternating cycles of Rituxan plus bendamustine and Rituxan plus cytarabine as induction therapy. The study pooled findings from two clinical trials and real-world experience.

Clinical Trial Results Leave Treatment Questions Unanswered for Certain Lymphomas

November 13th 2018

Lawrence D. Kaplan, M.D., discusses recent updates and next steps to be taken in Hodgkin, mantle cell and follicular lymphoma.

Single Agent Entospletinib Induces Modest Activity in Lymphoma Subgroups

November 13th 2018

Entospletinib monotherapy yielded limited activity in patients with relapsed or refractory indolent non-Hodgkin lymphoma and mantle cell lymphoma.

Imbruvica Yields Favorable Safety Outcomes in Two Types of Lymphomas

November 12th 2018

Imbruvica (ibrutinib) is a safe treatment for patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and mantle cell lymphoma (MCL), according to a pooled analysis of four clinical trials.